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Abstract  
 
This chapter describes a basic workflow for analysing the protein composition of 
influenza virions. In order to obtain suitable material, the chapter describes how to 
concentrate influenza virions from the growth media of infected cells and to purify 
them by ultracentrifugation through a density gradient. This approach is also suitable 
for purifying influenza virions from the allantoic fluid of embryonated chicken eggs. 
As a small quantity of microvesicles are co-purified with virions, optional steps are 
included to increase the stringency of purification by enriching material with viral 
receptor binding and cleaving activity. Material purified in this way can be used for a 
variety of downstream applications, including proteomics. As a detailed example of 
this, the chapter also describes a standard workflow for analysing the protein 
composition of concentrated virions by liquid chromatography and tandem mass 
spectrometry. 
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1 Introduction 
1.1 Virion concentration – a simple solution for simple assays 
This chapter describes how to concentrate and purify influenza virions, and then 
describes a straightforward workflow for identifying and quantifying all of the proteins 
they contain in a “bottom-up” proteomics approach.  
Detailed characterisation of influenza virions typically requires that they be 
concentrated. For some experiments purity is not an issue, and in such case a single 
round of ultracentrifugation can be very effective. As an example of how to do this 
(as shown in [1]): 
1. Clarify virus-containing medium or allantoic fluid either by 0.4-µm filtration or 
by centrifugation at top speed in a microcentrifuge (ca. 13,000 rpm) for 5 min. 
2. Layer 0.8 mL of the clarified sample onto an 0.5 mL cushion of 33% sucrose 
in PBS in an ultracentrifuge tube. 
3. Centrifuge at 91,000×g for 45 min at 4 °C in an ultracentrifuge. 
4. Aspirate the supernatant and resuspend the pellet in a suitable volume of 
buffer. 
While this approach is quick and straightforward, it will result in the co-purification of 
considerable amounts of contaminating material. For applications which detect 
specific components of the virion (e.g. qRT-PCR of viral gene segments, or Western 
blotting for individual viral proteins) such contamination may not be a concern. In 
other applications, particularly “omics” approaches which are not limited to a single 
target, contamination can be a serious problem. This chapter therefore presents 
methods for both concentrating and purifying virions. This can be used to prepare 
material for mass spectrometry, as described below, as well as for a wide range of 
other contamination-sensitive techniques. 
 
1.2 Virion purification 
Influenza virions can be purified in a multi-step ultracentrifugation protocol using a 
density gradient. However, even this approach cannot completely remove 
contaminants, and without additional increases in stringency the purified virions will 
be mixed with low but detectable levels of material whose protein composition is 
suggestive of ribosomes and microvesicles [2]. Microvesicles such as exosomes are 
shed by most host cells and due to their hydrodynamic radius and density they 
sediment at a similar position to influenza virions. To address this, this chapter 
presents two variants of the purification method which allow the stringency of 
purification to be adjusted (Fig. 1a, b). 
Firstly, there is the option of purifying virions through a gradient of iodixanol 
(OptiPrep™ Density Gradient Medium, Sigma) rather than sucrose. This has been 
reported to separate virions slightly from co-purifying microvesicles [3]. Secondly, 
chicken red blood cells (RBCs), which bind to but do not take up virus, can be used 
to purify material with both viral receptor binding and cleaving activities. This 
haemadsorption (HAd) step is very efficient at removing contaminants from the initial 
sample, but does introduce additional contaminants from the RBCs themselves and 
so is not suitable for all purposes [2]. Material purified as described should be 
suitable for detailed proteomic analysis. Detailed descriptions of the stringency of 
purification with and without haemadsorption can be found in [2]. 
The multi-step approach described here was optimised for purifying virions of 
laboratory-adapted influenza strains, which typically have a spherical morphology, 
and is adapted from [4]. In principle it could be adapted to separate out filamentous 
forms of the virus, but while this has been reported, it is often challenging in practice 
[5, 6]. Readers interested in adapting the purification methods described here to 
other viruses may wish to consult an online series of ultracentrifugation protocols, 
including mini-reviews of methods for a wide variety of viruses, maintained at the 
time of writing by the density gradient medium manufacturer Axis-Shield 
(http://www.axis-shield-density-gradient-media.com/methodology.htm). Before 
undertaking any work with viruses or ultracentrifugation, readers should familiarise 
themselves with the safety considerations for such work, as summarized in Note 1.  
 
1.3 Virion proteomics 
1.3.1 A simple proteomics workflow 
A wide variety of approaches are available for proteomic analysis, but in recent years 
mass spectrometry has become particularly powerful (reviewed in [7]). This chapter 
outlines a simple three-part workflow for determining the proteome of virions by 
mass spectrometry. 
First, sections 2.2 and 3.2 describe sample preparation, specifically how to 
prepare tryptic peptides from virions. 
Next, sections 2.3 and 3.3 outline the process of liquid chromatography and 
tandem mass spectrometry (LC-MS/MS) using a Q Exactive™ Hybrid Quadrupole-
Orbitrap Mass Spectrometer (Thermo Scientific). Despite the growing popularity of 
mass spectrometry methods, it is still likely that most readers will send samples to a 
specialist facility for analysis. In addition, those readers already operating a mass 
spectrometer will not need to look to this chapter for guidance on its use. Instead, 
this chapter will outline a standard set of conditions suitable for influenza virion 
proteomics, so that readers who do perform their own mass spectrometry can 
confirm that the conditions they are using are appropriate, and readers who out-
source this stage of analysis can gain a more detailed understanding of what is 
involved. 
Finally, sections 2.4 and 3.4 present a standard data analysis workflow for 
protein identification and quantitation using the open-source platform MaxQuant. 
More sophisticated analyses of the data are also possible, for example to identify 
sites of post-translational modification. For details of these, the reader is directed to 
a detailed recent protocol article on the various uses of MaxQuant [8].  
The principles underlying LC-MS/MS, as well as the principles behind sample 
preparation for this method and the analysis of mass spectra, are briefly explained 
below. 
 
1.3.2 Principles of LC-MS/MS 
There are a wide variety of approaches for obtaining and analysing mass spectra. 
The approach set out here has the following key features: 
 It is a bottom-up approach, which is to say that instead of analysing intact 
proteins (top-down proteomics) it analyses peptides generated by enzymatic 
digest. This approach is experimentally and computationally easier to 
implement [7]. 
 First, the peptides are separated by reversed-phase chromatography (liquid 
chromatography, LC). As they elute from the chromatography column, they 
are ionised and transferred into the vacuum of a mass spectrometer by 
electrospray ionisation (ESI) [9]. 
 In the instrument, peptide ions are captured and focused using magnetic 
fields. The method described here uses data-dependent acquisition (DDA). 
Under this method, ions that co-elute from the LC column are initially collected 
and their mass spectra are recorded (full scan, or MS1 spectra). Before the 
composition of the eluting ions changes, the most abundant of these 
‘precursor’ ions are sequentially selected from the LC column output using a 
quadrupole mass filter, fragmented using high-energy collisions, and the mass 
spectra of their ‘fragment’ ions also recorded (MS/MS, or MS2 spectra) to 
provide detailed information on the precursor ion’s composition. The 
instrument cycles between mass analysis of precursor ions and fragment 
ions, with each MS1 scan followed by a user-defined number of MS2 scans (in 
the ‘top 10’ approach described here, ten MS2 scans) [7, 9]. 
 The Q Exactive instrument described here detects mass spectra using an 
Orbitrap mass analyser. In an Orbitrap, ions are injected along a tangent into 
the cavity between two co-axial electrodes, the inner electrode being spindle-
shaped. Ions orbit rapidly around the inner electrode at a frequency 
proportional to their mass to charge (m/z) ratio, inducing a current. A Fourier 
transform is performed on this output to determine the frequencies and 
amplitudes of the currents induced by each species of ion, which can then be 
used to calculate their m/z ratios and abundance, respectively [9, 10]. 
 
1.3.3 Principles of sample preparation by FASP 
Bottom-up proteomics requires that proteins in the sample are digested into 
peptides. Trypsin is the most commonly used enzyme for generating peptides for 
mass spectrometry analysis. It has high proteolytic activity, cleaves specifically after 
lysine and arginine, unless followed by a proline, and the peptides generated have 
an optimal length and charge for analysis. However, trypsin digestion is rarely 
complete. For improved digestion of complex or difficult-to-digest samples, prior to 
trypsin digestion proteins can be digested with lysyl endopeptidase Lys-C, which 
cleaves after lysine regardless of the following residue. Lys-C proteolysis can occur 
in denaturing conditions of up to 6 M urea, allowing the digestion of proteolytically 
resistant proteins. 
A number of protocols are available for digesting proteins with trypsin, 
including digests of proteins in solution and in small sections of polyacrylamide gels. 
In this chapter we describe a procedure for filter-aided sample preparation (FASP), 
which uses a 10 kDa molecular weight cut-off (MWCO) filter to retain undigested 
proteins during washing [11]. This offers a number of advantages including the ability 
to wash out residual detergents, to remove non-protein components such as nucleic 
acids, and to bypass precipitation steps which are associated with substantial protein 
losses. Avoiding contamination is critical at this stage, and the guidelines in Note 2 
should be carefully adhered to. 
 
1.3.4 Principles of proteomic data analysis 
A number of software platforms are available for identifying and quantifying proteins 
from mass spectra. Here, we provide a brief protocol for using MaxQuant, a widely-
used open-source platform for the analysis of mass spectrometry-based proteomics. 
A detailed description of this powerful system has recently been published in a 
protocols paper, and the reader is referred to this for technical notes and further 
details of its capabilities [8]. 
Briefly, MaxQuant identifies proteins by matching mass spectra to a user-
supplied list of proteins. An in silico digest is performed to predict the peptide 
sequences that could be generated from these proteins, and their predicted mass 
spectra are calculated (both for the precursor ions and the fragment ions). Peptide 
spectral matches are then made between experimentally observed mass spectra 
and these theoretical spectra, allowing proteins in the user’s list to be identified. The 
false-discovery rate is controlled by a target-decoy database strategy. For this, a 
“decoy” database is generated by reversing the order of amino acids in the user-
supplied protein list and generating theoretical peptide mass spectra from that. 
These “decoy” spectra are also matched to the experimental data, and the 
stringency of acceptable matches is adjusted until only a small proportion of the 
protein groups identified (typically <1%) are from the decoy database. 
 
2 Materials 
2.1 Materials for virion concentration and purification 
2.1.1 Equipment for virion concentration and purification 
 Rotating wheel – optional. 
 Gradient Master (BioComp Instruments) – optional. 
 Refrigerator. 
 37 °C water bath. 
 Benchtop centrifuge with refrigeration (e.g. a Rotanta 460 R, Hettich Lab 
Technology). 
 Mass balance. 
 Ultracentrifuge (e.g. Beckman Coulter). 
 Beckman Coulter SW28 swinging bucket rotor or equivalent. 
 Beckman Coulter SW41 swinging bucket rotor or equivalent. 
 Aspiration vessel suitable for infectious material (e.g. an Integra Vacusafe) – 
optional. 
 -80 °C freezer. 
 
2.1.2 Consumables for virion concentration and purification 
 0.45-μm syringe filters. 
 50-mL syringes. 
 50-mL plastic tubes. 
 15-mL plastic tubes – optional. 
 Thickwall tubes for the SW28 rotor (polyallomer centrifuge tubes, 25 × 89 mm; 
Beckman Coulter; 355642). 
 Thinwall tubes for the SW41 rotor (polyallomer centrifuge tubes, 14 × 89 mm; 
Beckman Coulter; 331372). 
 5-mL syringe and needle (21 G or similar). 
 1.5-mL microfuge tubes. 
 Standard plasticware, pipettes, permanent marker pen. 
 
2.1.3 Reagents for virion concentration and purification 
 Virus-containing growth medium or allantoic fluid (see section 3.1.2, steps 2-
3). 
 10× NTC: 1 M NaCl, 0.2 M Tris-HCl pH 7.4, 50 mM CaCl2. 
 Sucrose, or OptiPrep™ density gradient medium (Sigma; D1556). 
 Phosphate-buffered saline (PBS). 
 H2O: HPLC-grade water can be used, though double-distilled water can also 
be used provided detergent contamination is scrupulously avoided (see Note 
2). Tap water should not be used. 
 RBCs: adult chicken blood cells in Alsever’s solution (TCS Biosciences; 
FB010) – optional. 
 
2.2 Materials for filter-aided sample preparation (FASP) 
2.2.1 Equipment for FASP 
 Microcentrifuge. 
 Vacuum centrifuge with cold trap for volatile organics (e.g. Thermo Scientific, 
SPD111V). 
 Spectrophotometer (set to 595 nm) and cuvettes for Bradford assay. 
 
2.2.2 Consumables for FASP 
 10,000 MWCO filter units (Vivacon 500, VN01H02). 
 
2.2.3 Reagents for FASP 
 For all buffers and solvents listed in this section use ultrapure water. 
 Bradford assay kit, for example Bio-Rad Protein Assay (500-0001). 
 ABC: Ammonium bicarbonate. 
 TFA: Trifluoroacetic acid. 
 TCEP: Tris(2-carboxyethyl)phosphine hydrochloride. 
 IAA: Iodoacetamide. Note: IAA is light sensitive. 
 ACN: Acetonitrile. 
 Lysis Buffer: 8 M urea and cOmplete protease inhibitor cocktail (Sigma) in 100 
mM ABC. 
 Wash Buffer I: 8 M urea in 100 mM ABC. 
 Wash Buffer II: 6 M urea in 25 mM ABC. 
 Lys-C: Lysyl Endopeptidase (Wako). 
 Sequence grade-modified trypsin (Promega). 
 
2.3 Materials for LC-MS/MS 
2.3.1 Equipment required for LC-MS/MS 
 Trap column: 5 mm, PepMap RSLC, C18, 300 μm I.D. particle size 3 μm 
(Thermo Scientific). 
 C18 reversed-phase capillary column: 50 cm, PepMap RSLC, EASY-spray 
column, C18, 75 μm I.D. particle size 3 μm (Thermo Scientific). 
 Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific) 
with a Dionex UltiMateTM 3000 HPLC (Thermo Scientific). 
 
2.3.2 Consumables for LC-MS/MS 
 V-bottom 96-well plate. 
 
2.3.3 Reagents for LC-MS/MS 
 ACN: Acetonitrile. 
 FA: Formic acid. 
 DMSO: Dimethyl sulfoxide. 
 Loading buffer: 5% FA, 5% DMSO. 
 Mobile phase A: 0.1% FA, 5% DMSO. 
 Mobile phase B: 100% ACN, 0.1% FA, 5% DMSO. 
 
2.4 Materials for Data Analysis 
2.4.1 Equipment for Data Analysis 
 A personal computer: MaxQuant is typically run with parallel execution on 
multiple cores, with no upper limit to the number of cores used provided the 
disk performance scales up with it. Each core should have at least 2 GB RAM. 
In addition to sufficient disk space to store the raw data files, at least half as 
much space should be available for temporary files generated during 
calculations. 
 
2.4.2 Software for Data Analysis 
 Operating System: Windows (64-bit) with .NET Framework 4.5 or higher, or 
Windows emulation software if using Mac computers. Linux is not currently 
supported. 
 MaxQuant: MaxQuant can be downloaded from http://www.maxquant.org 
(free registration required). This chapter describes the use of version 1.5.8.3. 
 MSFileReader, a standard library used to access raw files from Thermo 
instruments. At the time of writing, MaxQuant has been most thoroughly 
tested with MS File reader 3.0 SP2. Free registration is required at 
https://thermo.flexnetoperations.com/control/thmo/RegisterMemberToAccount 
after which it can be downloaded from 
https://thermo.flexnetoperations.com/control/thmo/login. 
 Data analysis software: The data generated here can be analysed with 
standard software such as Microsoft Excel or R (https://www.rstudio.com/). 
However, particularly for more complex analyses the reader is directed to 
Perseus, a freely-available programme developed to analyse proteomics data 
from MaxQuant (http://www.perseus-framework.org). 
 
3 Methods 
3.1 Method for virion concentration and purification 
3.1.1 Timings for virion concentration and purification 
1. Solution preparation: when convenient. 
2. Generation of virus: two to three days (see Notes 3 and 4). 
3. Harvesting and clarification: 40 min. 
4. Transfer, balance and clarification: 50 min. 
5 – 9. HAd (optional): 90 min. 
10. Layering onto cushions: 15 min. 
11. Ultracentrifugation: 120 min. 
12. Ultracentrifugation: 180 min. 
13. Ultracentrifugation: 80 min. 
Approximate time for purifications (steps 3 – 13): 8 hours without HAd, 9 and a half 
hours with HAd. 
 
3.1.2 Protocol for virion concentration and purification 
An overview of the standard protocol is given in Fig. 1a and of the haemadsorption 
(HAd) protocol in Fig. 1b. 
1. Prepare solutions in advance and store in the refrigerator – all should be 
used cold. Prepare: 
a. 1× NTC solution (from 10× stock). 
b. Working dilutions for the density gradient. 
(i) If pouring the gradient manually, to use sucrose, make 50 mL 
aliquots of 30, 40, 50, and 60% solutions (w/v) by adding the required 
mass of sucrose to 5 mL of 10× NTC and topping up with ddH2O. Mix 
on a rotating wheel until dissolved, then pass through a 0.45-μm 
syringe filter into a clean 50-mL tube. Mix equal amounts of these 
solutions in additional tubes to produce 35, 45, and 55% solutions 
(w/v). If using OptiPrep™, follow a similar procedure to prepare a 10 – 
40% (w/v) series of iodixanol solutions in NTC (OptiPrep™ is 60% 
iodixanol, so 12 mL solutions at 10, 20, 30, and 40% should contain 1.2 
mL of 10× NTC and 2, 4, 6, and 8 mL OptiPrep™, respectively). 
Intermediate concentrations (15, 25, and 35%) can be prepared by 
mixing, as above. 
(ii) If mixing the gradients using a Gradient Master, only the highest 
and lowest densities listed above are required. 
c. Pouring the density gradient (see Note 5 for optimisation). 
(i) To manually prepare a step gradient, layer 1.5 mL of each of the 
seven solutions into a thinwall tube. Starting with the most 
concentrated solution, use a pipette to slowly add layers, 0.75 mL at a 
time, taking care not to mix layers (the interfaces of different 
concentrations should remain visible). This is most easily done by 
tilting the tube to 45° and pipetting gently into the meniscus on 
the far (overhanging) wall of the tube (the same position is shown 
being used to overlay media on to a cushion in Fig 2a, b). Gradients 
can be prepared in advance and stored at 4 °C (some mixing by 
diffusion is acceptable); if prepared during the purification this can be 
done during the first ultracentrifugation step. 
(ii) Alternatively, a continuous gradient can be rapidly prepared using a 
Gradient Master (BioComp), if available. This tilts a stoppered tube 
containing two densities of solution until their interface runs diagonally 
from the meniscus to the bottom edge of the tube, then rotates around 
an axis parallel with the tube to mix the two solutions together. To do 
this, place the thinwall tube in the correct holder and use the rim of the 
holder to mark the halfway point with a pen, fill with the upper (least 
dense) medium up to the mark, then use a syringe with a long cannula 
to gently underlay with the lower (most dense) medium until the 
interface reaches the mark. Then stopper the tube, place on the 
Gradient Master, and tilt to 80° before rotating for 2 min at 18 rpm (for 
30 – 60% sucrose) or for 50 s at 20 rpm (for 10 – 40% iodixanol). 
(iii) If only one gradient is required a balance can be quickly prepared 
by mixing 5.25 mL of the most and least concentrated solutions, or 
simply using 10.5 mL of the middle concentration. 
d. If performing HAd, prepare chicken blood. To prevent lysis, blood 
should be centrifuged at no more than 1,250×g (around 2,500 rpm if 
using 15-mL tubes in a benchtop centrifuge, depending on the rotor) 
and at no colder than 10 °C. Although the blood should be kept 
chilled (e.g. in a fridge) it should not be put directly on ice. On receipt, 
cells should be rinsed twice in chilled PBS. Comparison of the cell 
pellet to a measured volume of liquid in an equivalent tube should be 
used to estimate the volume of cells, and the pellet resuspended in 
PBS to 20% packed cell volume (pcv) for storage in the refrigerator. If 
haemolysis occurs during storage (visible by the PBS becoming pink) 
the cells should be rinsed again in PBS and resuspended in an 
appropriate volume. When about to begin purification, pre-warm an 
aliquot of PBS to 37 °C. 
2. Prepare virus to be concentrated (see Note 4). A maximum of 150 mL of 
virus-containing medium can be prepared without prior HAd. This can be 
obtained from six 175-cm2 tissue culture flasks which have been seeded with 
a suitable cell line (e.g. Madin-Darby Bovine Kidney or Madin-Darby Canine 
Kidney cells), infected when sub-confluent with an influenza virus at a low 
multiplicity of infection, and maintained at 37 °C in a humidified incubator for 
approximately 48 h, depending on the strain. Alternatively, cells can be 
seeded into roller bottles, which allow a larger surface area of cells to be 
maintained in a smaller volume of medium (e.g. 40 mL of medium in an 850-
cm2 bottle). 
3. When the virus is ready to harvest, extensive cytopathic effect is likely be 
apparent by microscopy (though this is somewhat strain-dependent, and for 
some strains prior determination of the optimal growth conditions may be 
required; see Note 3). Transfer the media to six 50-mL tubes and centrifuge 
at 4 °C for 10 min at approximately 2,000× g (around 4,000 rpm, depending 
on the rotor) to pellet cellular debris. 
4. Transfer the supernatant to six (thickwall) tubes and place in the buckets of an 
SW28 rotor. Weigh the buckets (with the lids on) and transfer media 
between them as necessary to balance. Centrifuge at 4 °C for 10 min at 
18,000×g (10,000 rpm) in an SW28 rotor (or equivalent) to further pellet 
cellular debris. Retain 1 mL sample for analysis (optional). 
If extremely high purity is required (and chicken red blood cell contaminants are not 
problematic) perform HAd as described in steps 5 – 9. Otherwise, proceed to step 
10. 
5. Optional. Transfer supernatants to six clean, chilled 50-mL tubes and add 325 
μL of RBCs (20% pcv) to each tube. Mix by gentle inversion and refrigerate 
for 30 min, inverting regularly. Pellet cells with bound virus (1,250×g or around 
2,500 rpm depending on the rotor, 5 min, 10 °C). Remove and discard 
supernatant, retaining 1 mL sample for analysis (optional). 
6. Optional (cont.). Resuspend all six cell pellets in a single aliquot of 10 mL 
chilled PBS. To do so, sequentially rinse each tube with the same 5 mL 
aliquot of PBS, repeat with a second 5 mL aliquot, and pool both aliquots into 
a single 15-mL tube. Pellet cells (1,250×g or around 2,500 rpm depending on 
the rotor, 5 min, 10 °C). Remove and discard supernatant, retaining 1 mL of 
sample for analysis (optional). 
7. Optional (cont.). Resuspend pellet in 10 mL of chilled PBS (some 
agglutination of cells may be apparent). Pellet cells (1,250×g or around 2,500 
rpm depending on the rotor, 5 min, 10 °C). Remove and discard supernatant, 
retaining 1 mL sample for analysis (optional). 
8. Optional (cont.). Resuspend pellet in 10 mL 37 °C PBS, transfer to a clean, 
room-temperature 50-mL tube and increase the volume to 20 mL with 37 °C 
PBS. Incubate at 37 °C for 15 min, mixing regularly by gentle inversion. Pellet 
cells (1,250× g or around 2,500 rpm depending on the rotor, 5 min, 10 °C), 
retain supernatant and take 100 μL for analysis (optional). 
9. Optional (cont.). Prepare two thickwall tubes with 5 mL chilled 30% sucrose or 
10% iodixanol. Gently layer the supernatant onto the 5 mL cushion, using 
gravity flow and taking care not to mix the layers (the interface should remain 
visible) (see Note 6). Add 20 mL of PBS or water to the second tube to 
balance. Place the tubes in SW28 rotor buckets (or equivalent) and weigh 
with the lids on; adjust the volume of the balance tube as necessary. Proceed 
to step 11. 
10. If HAd was not performed, prepare 6 thickwall tubes with 5 mL of chilled 30% 
sucrose or 10% iodixanol in each. As shown in Fig. 2a–c, gently layer the 
supernatants onto the 5 mL cushions, using gravity flow and taking care not to 
mix the layers (the interface should remain visible) (see Note 6). Place the 
tubes in SW28 rotor buckets (or equivalent) and weigh with the lids on; adjust 
the volumes as necessary to balance across the rotor. 
11. Pellet virions by ultracentrifugation at 4 °C for 90 min at 112,000×g (25,000 
rpm). As shown in Fig. 2d, aspirate the supernatants, taking care not to 
disturb the pellet (which may not be visible, see Note 7). When nearing the 
bottom of the tube, run the pipette around the meniscus and tilt the tube to 
separate the supernatant from the pellet. As shown in Fig. 2e, add 50 μL of 
chilled 1× NTC to each tube (or around 500 μL to the single tube if HAd was 
used) and resuspend by pipetting up and down (see Note 7). Pool the 
suspension in a clean 1.5 mL microfuge tube and then, as shown in Fig. 2f, 
layer it gently onto the top of a density gradient (see step 1c, above) taking 
care not to mix the layers. Place the gradient tube and a balance tube into 
SW41 rotor buckets (or equivalent) and weigh with the lids on; adjust the 
volumes as necessary to balance across the rotor. 
12. Pellet virions by ultracentrifugation at 4 °C for 150 min at 209,000×g (35,000 
rpm). Afterwards, the virions should be visible as a milky band of material at 
around 40% sucrose or 30% iodixanol (Fig. 2g). Illuminating the gradient from 
above and holding the tube against a dark background may make the band 
easier to see. Use a pen to mark the position of the virions and of the 
meniscus, then mark a point below the virions where the tube will be 
punctured and a point below the meniscus to indicate how much fluid 
should be withdrawn (around 1 cm of the gradient height, or 1 – 2 mL). 
Prepare an autoclavable sharps disposal bin, secure the tube above a waste 
pot and, using a 5-mL syringe and needle, carefully pierce the side of the tube 
a few millimeters below the virions, with the bevelled opening of the needle 
facing upwards. While moving the needle tip gently forwards and backwards, 
withdraw fluid from the gradient, including the band of virions, using the pen 
mark below the meniscus as a guide to the amount taken (Fig. 2h). Withdraw 
the needle and quickly transfer the pierced tube into the waste pot. As shown 
in Fig. 2i, eject the contents of the syringe into a new thinwall tube containing 
9 mL of chilled 1× NTC, and rinse out the syringe once in this solution. 
Transfer the needle and syringe immediately to the sharps bin. Place the tube 
and a balance tube in SW41 rotor buckets (or equivalent) and weigh with the 
lids on; adjust the volumes as necessary to balance across the rotor. 
13. Pellet virions by ultracentrifugation at 4 °C for 60 min at 154,000×g (30,000 
rpm). Aspirate the supernatant, taking care not to disturb the pellet. Add 
around 80 μL of chilled 1× NTC and resuspend by pipetting; this should give 
around 150 μL of a milky solution of purified virions. Reserve around 10% for 
analysis, and store the rest in a 1.5 mL tube at -80 °C. 
 
3.1.3 Anticipated results of virion concentration and purification 
The method described should result in a thousand-fold decrease in volume with, 
typically, a 10 – 30% recovery of infectious material (plaque-forming units). As some 
virus will be inactivated during purification the total recovery of material is likely to be 
better than this. Electron microscopy shows that virions generally remain intact 
during purification (Fig. 1c) and SDS-PAGE and silver staining of a small proportion 
(around 1 – 5%) of the recovered material should show good recovery of viral 
proteins (Fig. 1d) [1, 11]. For guidance on troubleshooting, see Note 8. 
Purification without HAd is sufficient to remove the majority of contaminating 
material, as can be seen by SDS-PAGE and silver staining [2, 12], and this is likely 
to be sufficient for the majority of applications. However, low levels of contaminants 
are still present when material is purified in this way [2]. These contaminants can be 
excluded by HAd, though this method introduces additional contaminants derived 
from chicken red blood cells [2]. Readers interested in the presence of specific 
protein contaminants after purification with and without HAd are referred to the 
supplementary tables of [2]. 
 
3.2 Method for FASP 
1. Lyse purified virions by mixing 1:1 with Lysis Buffer and incubating for 30 min 
at room temperature, vortexing occasionally. As well as rendering the 
samples suitable for analysis, this will render the virus non-infectious. Do not 
heat above room temperature; this accelerates carbamylation of proteins 
and is unnecessary for inactivating influenza viruses. If a substantial insoluble 
pellet remains, detergent may be added (e.g. SDS), but this will increase the 
number of washing steps required for FASP and should be kept to a 
minimum. Never use polyethylene glycol (PEG) for inactivating the virus 
(see Note 2). 
2. Clear lysate (15,000×g, 15 min) and collect the protein-containing 
supernatant. 
3. Take an aliquot and estimate the protein concentration by Bradford assay. If 
dilution is necessary, dilute the aliquot, not the total lysate. This assumes the 
lysate is free of detergent, as recommended. If not, a BCA assay should be 
used. 
4. Assemble the filter units (Fig. 3a, b) and wash them with 200 µL of 0.1% TFA 
in 50% ACN (14,500× g, 15 min). There should be no more than a thin film of 
liquid remaining on the filter after centrifugation. Increase the centrifugation 
time if necessary. 
5. Discard flow-through from the collection tube. 
6. Equilibrate the filter units by spinning through 200 µL of Wash Buffer I. 
7. Load the lysate onto the filter by spinning it through (Fig. 3c). Note that: 
a. Proteins with a MW greater than 10 kDa will be retained on the filter, 
but smaller proteins will be lost. 
b. A maximum of 400 µg of total protein can be loaded per filter, but if no 
further downstream peptide enrichment or fractionation is carried out 
(neither is required for the standard virion analysis) aim to digest 10-20 
µg lysate. 
c. Multiple loading steps may be required if the volume exceeds 400 µL. 
d. High amounts of proteins can increase the centrifugation time.  
8. To reduce the sample with 10 mM TCEP, add 4 µL of 0.5 M TCEP into 200 µL 
of Wash Buffer I, and add to the filter and incubate for 30 min at room 
temperature (Fig. 3d). 
9. To alkylate the protein with 50 mM IAA, further add 20 µL of 0.5 M IAA and 
incubate for another 30 min at room temperature (Fig. 3d). Keep the samples 
in the dark for this step as IAA is light sensitive (see Note 9). 
10. Spin to remove the reduction and alkylation buffer, and discard this. 
11. Detergent-containing samples need to be washed extensively with 200 µL 
Wash Buffer I until the flow-through no longer forms bubbles when shaken. 
12. Wash the filter with 200 µL of Wash Buffer II to reduce the urea concentration 
to 6 M. 
13. Repeat step 12. 
14. Change to a fresh collection tube for peptide collection. 
15. To digest the lysate with Lys-C, add 100 µL of Wash Buffer II containing Lys-
C at a final Lys-C:protein ratio of 1:40 (w/w), and incubate for 1–3 h at 37 °C.  
16. To digest the lysate with trypsin, add 300 µL of 25 mM ABC to dilute the urea 
to 1.5 M, including trypsin at a final trypsin:protein ratio of 1:40 (w/w). Digest 
overnight at 37 °C. 
17. Harvest peptides by spinning them through the filter (Fig. 3e). Retain the 
peptide-containing flow-through and pool with the flow-through from 
subsequent steps 18 and 19.  
18. Wash remaining peptides off the filter with 200 µL of 0.1% FA and retain. 
19. Repeat step 18 with 200 µL of 0.1% FA in 50% ACN. Pool flow-through from 
steps 17, 18, and 19. 
20. Dry down peptides in a vacuum centrifuge until the solution has evaporated. 
 
3.3 Method for LC-MS/MS 
1. Reconstitute the peptides in loading buffer and add the sample to a V-bottom 
96-well plate. 
2. Place the plate in the Dionex UltiMateTM 3000 autosampler (Fig. 3f). 
3. Inject sample. Peptides should be desalted on-line by a trap column, 
separated on an analytical C18 reversed-phase capillary column (flow rate: 
200 nL/min, gradient: 7–30% (v/v) mobile phase B over 60 min, column 
temperature: 45 °C) and analyzed by the Q Exactive Hybrid Quadrupole-
Orbitrap mass spectrometer (Fig. 3g). 
4. Acquire data in data-dependent acquisition (DDA) mode, automatically 
switching from MS to collision induced dissociation MS/MS on the top 10 most 
abundant ions with a precursor scan range of 350 – 1650 m/z. 
5. Reject 1+ charge states. 
6. Acquire full scan MS spectra at a resolution of 70,000 and MS/MS scans at 
17,000 at a target value of 3 × 106 and 1 × 105 ions respectively. 
7. Enable dynamic exclusion with an exclusion duration of 40 s. 
 
3.4 Method for data analysis 
3.4.1 Preparation for data analysis 
1. To analyse the virion proteome supply the viral proteome, the host proteome 
and, if HAd was used, the chicken proteome. The host and chicken (Gallus 
gallus) proteomes can be downloaded from UniProt 
(http://www.uniprot.org/proteomes/). Proteome IDs of organisms commonly 
used to grow influenza virus in culture are: 
Host Organism Proteome ID (UniProt) 
Human (Homo sapiens) UP000005640 
Chicken (Gallus gallus; from chicken 
RBCs and infected eggs) 
UP000000539 
Dog (Canis lupus familiaris; from MDCK 
cells) 
UP000002254 
Cow (Bos taurus; from MDBK cells) UP000009136 
 Download proteomes by navigating to the relevant page on UniProt and 
selecting “Download all protein entries / FASTA (canonical).” 
2. To generate a viral proteome write a FASTA file. This can be done simply on 
any text editor. Readers unfamiliar with the format are referred to Note 10. 
Users will often already know the sequence of their virus. If not, it can often be 
found through searching online repositories such as the NCBI Influenza Virus 
Resource (https://www.ncbi.nlm.nih.gov/genome/viruses/variation/flu/) or the 
Global Initiative on Sharing All Influenza Data (GISAID; platform.gisaid.org/), 
though be aware that viral strains typically acquire mutations during passage, 
and any peptides which do no match precisely to the supplied sequence will 
not be identified. To date, the only viral proteins to have been identified in 
influenza virions are PB2, PB1, PA, HA, NP, NA, M1, M2, NS1 and NEP [2]. 
However, the virus encodes other proteins, both experimentally confirmed and 
predicted, and the user may wish to search for these as well. As an example 
of this, and as an example of the FASTA format, the proteome of the 
commonly used laboratory strain influenza A/Puerto Rico/8/1934 (H1N1) virus 
is given in Note 11. 
3. Next, configure the database so that MaxQuant can read it. To do so, open 
MaxQuant and go to the Configuration/Sequence databases tab. Click “Add” 
to add a new database configuration (many standard databases are already 
configured). This will create a new line at the bottom of the database table, 
and create editable settings on the right. Use “Fasta file name” to select your 
fasta file (do not change its name, as it is required for MaxQuant to recognize 
it). If you wish you may specify the source and taxonomy of the file. Clicking 
arrows will fill in the taxonomy name from the taxonomy number, and vice 
versa. Importantly, you must insert the correct identifier parse rule to allow 
MaxQuant to extract information from the headers (sequence names) in your 
fasta file. These are written using regular expressions, and can either be 
copied from one of the existing entries in the sequence configuration table, 
entered using the “Select” buttons next to each rule, or copied from this table: 
Identifier parse rule Meaning 
>(.*) Everything after the “>”. Includes the full 
header supplied for any fasta sequence, 
creating a rather cluttered output table 
but including gene names, etc., as well 
as accessions. 
>([^]) Everything after the “>” up to the first 
space (suitable for the custom virus 
database in Note 11, as is the rule 
above). 
>IPI:([^|\.]*) IPI accession. 
>(gi\|[0-9]*) NCBI accession. 
>([^\t]*) Everything after the “>” up to the first 
tab. 
>.*\|(.*)\| Uniprot ID (suitable for the UniProt 
databases suggested above). 
 
To check the entry is correct, click “Test rules” and use the button to 
download entries from your fasta file to check that, at a minimum, the Header, 
Sequence and Identifier can be correctly read. 
4. To save your changes, first click “Modify Table” (to transfer changes from the 
editing box on the right to the table on the left) then click “Save changes”. 
Finally, close MaxQuant for the changes to take effect. 
 
3.4.2 Protocol for Data Analysis 
1. Open MaxQuant. Most default settings will be suitable, but the following points 
are either experiment-dependent or important for understanding the analysis. 
2. Set the number of threads (bottom left) to the number of files to be searched 
or the highest number supported by your computer, whichever is lower. 
3. Click the Raw Files / Load button and load raw files for each virus to analyse. 
If loading more than one raw file, set an experimental design using the 
buttons in the Raw Files tab. For analysing separate sets of virions it may be 
simplest to set each raw file as a separate experiment (“No fractions”). 
4. In the Group Specific Parameters / General tab the Type should be ‘Standard’ 
and the Multiplicity ‘1’ (assuming no labelling strategy, such as SILAC or 
tandem mass tagging, has been used). ‘Variable Modifications’ (post-
translational modifications (PTMs) which are only occasionally found) should 
include Acetyl (Protein N-term) and Oxidation (M). Other PTMs can be added, 
including biologically relevant ones such as phospho (STY) or artifactual ones 
such as deamidation (NQ) by selecting the modification on the left-hand menu 
and using the arrow button to add it to the list on the right. Note that 
increasing the number of PTMs simultaneously searched for will significantly 
increase processing time. Digestion mode should be Specific, with the 
enzyme Trypsin/P (i.e. tryptic (KR) cleavage sites, including sites followed by 
proline that would be cleaved by Lys-C) and a maximum number of missed 
cleavages of 2. 
5. In the Group Specific Parameters / Label-Free Quantitation tab, label-free 
quantitation should be set to ‘LFQ.’ This will allow relative protein abundance 
to be estimated based on the intensity with which peptide ions were detected 
in the instrument, incorporating several layers of normalisation [13]. 
6. In the Global Parameters / General tab, upload the FASTA files for your host 
and viral proteomes (these can be uploaded as multiple separate files). 
MaxQuant will also include a list of common contaminants in the search 
provided the relevant box is ticked. The Fixed Modifications list (PTMs 
applying to all relevant amino acids) should contain only ‘Carbamidomethyl 
(C).’  
7. In the Global Parameters / Label-Free Quantitation tab, select iBAQ. This 
enables intensity-Based Absolute Quantitation, an algorithm which adjusts 
peptide intensities based on the number of theoretically observable peptides 
from each protein [14]. LFQ provides better comparison between samples due 
to its normalisation steps, while iBAQ is a better indicator for absolute protein 
abundance [15]. 
8. Press ‘Start’ (bottom left). Depending on the computer and number of 
samples the programme may take some hours to run (days for larger 
experiments or slower machines). 
9. MaxQuant will typically write a large number of output files to the directory the 
raw files are in. For identifying and quantifying proteins, the most relevant files 
are tab-delimited tables written as text files in the subdirectory 
…/combined/txt. In particular, the file proteinGroups.txt contains information 
about the proteins identified. These files can be opened in MaxQuant’s 
Perseus package, or in a general purpose spreadsheet program such as 
Microsoft Excel. 
10. The proteinGroups file presents rows of ‘protein groups,’ or proteins that could 
be reconstructed from a common set of peptides. Of the many output columns 
in the proteinGroups file, the following are most likely to be of interest during 
an initial examination of the data: 
a. Protein IDs. Lists the proteins in the protein group, ranked by the 
number of peptides matched to each and separated by semicolons.  
Proteins with at least half as many peptides matched as the leading 
protein are also listed in the Majority Protein IDs column. 
b. Some protein groups should be disregarded, either because they are 
found in a list of common contaminants or because they are matches 
to the reversed decoy database. The columns ‘Potential contaminant’ 
and ‘Reverse’ mark these proteins, whose names in the Protein IDs 
column will also start with CON and REV, respectively. Proteins 
marked in the column ‘Only identified by site’ have only been identified 
by a modification site, and the user may choose to disregard these as 
well. 
c. Fasta Headers returns the original descriptions of the proteins. 
d. Peptide counts (all) gives the number of peptides matched to each 
member of the protein group. 
e. The Molecular Weight can be useful for some calculations. 
f. The LFQ Intensity returns the LFQ score and iBAQ returns the iBAQ 
score. 
 
3.4.3 Anticipated results of data analysis 
As an example of the results that may be obtained, a sample of influenza A/Puerto 
Rico/8/1934 (H1N1) virions was grown on MDCK (canine) cells and purified without 
haemadsorption. This has been described in a previous publication [2] and the raw 
data file C130708_055.raw may be downloaded from the Mass spectrometry 
Interactive Virtual Environment (MassIVE; Center for Computational Mass 
Spectrometry at University of California, San Diego) at 
http://massive.ucsd.edu/ProteoSAFe/datasets.jsp using the MassIVE ID 
MSV000078740. A copy of MaxQuant was downloaded and configured to analyze 
the data, as described above, using the UniProt dog proteome described above 
(downloaded on the 25th April 2017) and the viral proteome described in Note 11. 
The proteinGroups.txt file contained 653 proteins groups. Of these, 11 were 
only identified by site, 7 were from the decoy database and 12 were potential 
contaminants, with some overlap between these categories. Removing these left a 
list of 10 viral proteins and 615 host proteins (most of very low abundance). The 
abundance of these proteins is summarised in Fig. 4, using the relative iBAQ (riBAQ) 
score – a normalised abundance score obtained by dividing each protein’s iBAQ 
score by the total iBAQ scores of all proteins under consideration [16]. 
 
4 Notes 
1. Safety Considerations: This protocol is written for influenza viruses which can 
be handled at Advisory Committee on Dangerous Pathogens Containment 
Level 2 / Biological Safety Level 2 (specifically, for low-pathogenicity strains of 
influenza virus), and assumes that users are familiar with the safe handling of 
such viruses. Changes to the protocol would be required if a highly-
pathogenic strain of influenza virus was to be used. In all cases, work should 
be carried out in compliance with all applicable local and national biological 
safety regulations.  
 Ultracentrifuges should only be used in accordance with the 
manufacturer’s instructions and full buckets, with lids attached, should be 
balanced across the rotor to within 0.1 g using a mass balance. This is often 
easiest if a lightweight pot or rack is placed on the balance and used to 
hold the bucket. 
 Thickwall centrifuge tubes can be re-used unless they show signs of 
wear (check particularly around the joint between the straight and curved 
sections). After use they should be disinfected by an approved route (e.g. 
soaking in 1% Virkon™) followed by several washes in water, then in 70% 
ethanol, and finally by wiping out thoroughly with paper towel, paying 
particular attention to the bottom of the tube. Thinwall centrifuge tubes should 
not be re-used. 
2. Avoiding Contaminants: Mass spectrometry is an extremely sensitive 
approach which can detect even minute levels of contaminants. Two in 
particular regularly cause problems. 
a. Keratin. Human skin, hair and the resulting dust make keratin a ubiquitous 
contaminant – it is, as one researcher put it, always snowing in the lab. It 
is almost impossible to exclude keratin, but it can be minimised by keeping 
plasticware covered when not in use, working wherever possible in a 
laminar flow hood or microbiological safety cabinet, wearing and frequently 
changing gloves, and avoiding the use of communal chemical stocks. 
b. Polyethylene glycol (PEG). This widely-used compound is strongly ionised 
in the mass spectrometer and causes a repeating 44 Da signal that can 
swamp informative mass spectra. PEGylated detergents include 
commercial soaps, Tween, SDS, Triton X-100 and NP-40. Even minute 
quantities of PEG can compromise an experiment, and while some PEG 
can be removed by washing during sample preparation for mass 
spectrometry it should be avoided wherever possible. Disposable 
plasticware should be used where possible. When making buffers, do not 
re-use glassware that could previously have contained PEG and ensure 
any traces of soap have been washed off the glass with hot water followed 
by a rinse with an organic solvent such as acetonitrile. Finally, do not store 
buffers containing organic solvents in plastic containers, as this can leach 
PEG from the plastic. 
3. Virus Growth: Growth of virus can be assessed before beginning by 
microscopic examination of cells. For laboratory-adapted strains if no 
cytopathic effect (i.e. cell rounding or detachment) is visible it is unlikely that 
there will be enough virus to purify, though if working with an unfamiliar strain 
it is worth optimising growth conditions before proceeding to the purification. 
4. Quantities of Virus: For a well-adapted laboratory strain such as PR8 or WSN, 
we typically find that around 109 PFU (1010 – 1011 particles) of unpurified stock 
will give a clear band on a gradient as in section 3.1.2, steps 12 and 13. 
However the band may be faint and a dark background may be necessary in 
step 12. Additional bands may appear in step 12 depending on the mixing of 
the gradient steps and on the morphology of the virus. For most applications 
the major band can be harvested, but if this is ambiguous the entire gradient 
can be harvested in aliquots from the top by pipetting from the meniscus (step 
13 is then not required). 
5. Gradient Mixing: If gradient mixing needs to be checked a test gradient can be 
prepared in which one or more of the densities contain a dye such as 
Coomassie Brilliant Blue. 
6. As when pouring a step gradient, this can be easier to do if pipetting into the 
meniscus on the far (overhanging) side of a tilted tube (see Fig 2 a,b).  
7. Visibility of Pellets: Pellets may not be visible before the final concentration 
step (section 3.1.2, step 11) but can still be resuspended by pipetting. The 
final concentrated stock of virus should appear at least faintly milky. Methods 
for resuspending the pellet can vary. The author (EH) pipettes rapidly up and 
down twenty times, moving the tip around the area of the pellet while gently 
touching the bottom of the tube and taking care not to introduce bubbles. 
8. Troubleshooting: Samples taken throughout the purification can help to 
identify problems. A number of assays can be used to detect virions, including 
plaque assay (to detect fully infectious virions – typically recovery of infectious 
material is around 10 – 30%) and SDS-PAGE followed by silver staining (to 
assess purity and protein yield; Fig. 1c). If chicken blood is available a quick 
assay for the presence of virions (whether infectious or not) can be performed 
while other steps are being carried out using a modified haemagglutination 
(HA) assay: 
a. In a 96-well round-bottomed dish add 50 μL PBS to 11 of the 12 
columns, leaving the first column empty (a multi-channel pipette is 
helpful throughout this assay). 
b. In the first column add 100 μL of sample or PBS and perform twofold 
serial dilutions of this by transferring 50 μL into the second column, 
mixing, changing pipette tip and repeating across the dish. Up to eight 
samples can be assayed per dish; material from the final step in the 
purification is highly concentrated and so should only be used if heavily 
diluted beforehand, for example by 100-fold. 
c. Add 50 μL chicken red blood cells (at 1% pcv) to each well, mix and 
leave to stand, preferably at 4 °C. 
d. For each sample the last dilution in which the blood cells agglutinate 
and cannot settle to the bottom of the well contains one 
haemagglutinating unit (HAU). 
Note that, as this is a modification of the standard assay, the HAU values here 
are useful only for relative measures and should not be directly compared to 
other HA assays. Note also that the assay is rather insensitive to low 
concentrations of virus. Typical end-points (for a laboratory-adapted virus) are 
1/128 for the input material (in 120 mL) and 1/512 after HAd (in 20 mL – i.e. 
around 2/3 recovery of material). 
9. Spurious Ub sites: If the data are likely to be searched for sites of 
ubiquitination (not described in detail here, but a straightforward modification 
to the MaxQuant search is described in [8]), the iodoacetamide (IAA) used in 
the alkylation step should be substituted for a different alkylating agents such 
as chloroacetamide. This is because in addition to alkylating cysteines as 
intended, iodoacetamide can alkylate lysine residues. This can create a 2-
acetamidoacetamide covalent adduct with the same atomic composition as 
the diglycyl tag which remains after tryptic cleavage of covalently-bound 
ubiquitin. Reducing with IAA can therefore lead to the identification of spurious 
ubiquitination sites [17]. 
10. The FASTA file format: This is simply a text file in the format below. The file 
extension should be unimportant, but if required the file extension of a plain 
text file can be changed to ‘.fasta’. 
>NAME_1 
sequence 1 
>NAME_2 
sequence 2 
>NAME 3 
sequence 3 
11. The proteome of Influenza A/Puerto Rico/8/1934 virus in FASTA format, 
based on the reverse genetics virus with GenBank Accession numbers 
EF467817 - EF467824 [18]: 
>PB2 
MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMA
MKYPITADKRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRN
GPITNTVHYPKIYKTYFERVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLS
AKEAQDVIMEVVFPNEVGARILTSESQLTITKEKKEELQDCKISPLMVAYMLE
RELVRKTRFLPVAGGTSSVYIEVLHLTQGTCWEQMYTPGGEVRNDDVDQS
LIIAARNIVRRAAVSADPLASLLEMCHSTQIGGIRMVDILRQNPTEEQAVDICK
AAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGYEEFT
MVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDL
NFVNRANQRLNPMHQLLRHFQKDAKVLFQNWGVEPIDNVMGMIGILPDMTP
SIEMSMRGVRISKMGVDEYSSTERVVVSIDRFLRIRDQRGNVLLSPEEVSET
QGTEKLTITYSSSMMWEINGPESVLVNTYQWIIRNWETVKIQWSQNPTMLY
NKMEFEPFQSLVPKAIRGQYSGFVRTLFQQMRDVLGTFDTAQIIKLLPFAAA
PPKQSRMQFSSFTVNVRGSGMRILVRGNSPVFNYNKATKRLTVLGKDAGTL
TEDPDEGTAGVESAVLRGFLILGKENKRYGPALSINELSNLAKGEKANVLIGQ
GDVVLVMKRKRDSSILTDSQTATKRIRMAIN 
>PB2-S1 
MERIKELRNLMSQSRTREILTKTTVDHMAIIKKYTSGRQEKNPALRMKWMMA
MKYPITADKRITEMIPERNEQGQTLWSKMNDAGSDRVMVSPLAVTWWNRN
GPITNTVHYPKIYKTYFERVERLKHGTFGPVHFRNQVKIRRRVDINPGHADLS
AKEAQDVIMEVVFPNEVGARILTSESQLTITKEKKEELQDCKISPLMVAYMLE
RELVRKTRFLPVAGGTSSVYIEVLHLTQGTCWEQMYTPGGEVRNDDVDQS
LIIAARNIVRRAAVSADPLASLLEMCHSTQIGGIRMVDILRQNPTEEQAVDICK
AAMGLRISSSFSFGGFTFKRTSGSSVKREEEVLTGNLQTLKIRVHEGYEEFT
MVGRRATAILRKATRRLIQLIVSGRDEQSIAEAIIVAMVFSQEDCMIKAVRGDL
NFVNRANQRLNPMHQLLRHFQKDAKVLFQNWGVEPIDNVMGMIGILPDMTP
SIEMSMRGVRISKMGVDEYSSTERVVPLHQSKVECSSPHLL 
>PB1 
MDVNPTLLFLKVPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRTHQYSE
KGRWTTNTETGAPQLNPIDGPLPEDNEPSGYAQTDCVLEAMAFLEESHPGI
FENSCIETMEVVQQTRVDKLTQGRQTYDWTLNRNQPAATALANTIEVFRSN
GLTANESGRLIDFLKDVMESMNKEEMGITTHFQRKRRVRDNMTKKMITQRT
MGKKKQRLNKRSYLIRALTLNTMTKDAERGKLKRRAIATPGMQIRGFVYFVE
TLARSICEKLEQSGLPVGGNEKKAKLANVVRKMMTNSQDTELSFTITGDNTK
WNENQNPRMFLAMITYMTRNQPEWFRNVLSIAPIMFSNKMARLGKGYMFE
SKSMKLRTQIPAEMLASIDLKYFNDSTRKKIEKIRSLLIEGTASLSPGMMMGM
FNMLSTVLGVSILNLGQKRYTKTTYWWDGLQSSDDFALIVNAPNHEGIQAG
VDRFYRTCKLLGINMSKKKSYINRTGTFEFTSFFYRYGFVANFSMELPSFGV
SGINESADMSIGVTVIKNNMINNDLGPATAQMALQLFIKDYRYTYRCHRGDT
QIQTRRSFEIKKLWEQTRSKAGLLVSDGGPNLYNIRNLHIPEVCLKWELMDE
DYQGRLCNPLNPFVSHKEIESMNNAVMMPAHGPAKNMEYDAVATTHSWIP
KRNRSILNTSQRGVLEDEQMYQRCCNLFEKFFPSSSYRRPVGISSMVEAMV
SRARIDARIDFESGRIKKEEFTEIMKICSTIEELRRQK 
>PB1-N40 
MDTVNRTHQYSEKGRWTTNTETGAPQLNPIDGPLPEDNEPSGYAQTDCVL
EAMAFLEESHPGIFENSCIETMEVVQQTRVDKLTQGRQTYDWTLNRNQPAA
TALANTIEVFRSNGLTANESGRLIDFLKDVMESMNKEEMGITTHFQRKRRVR
DNMTKKMITQRTMGKKKQRLNKRSYLIRALTLNTMTKDAERGKLKRRAIATP
GMQIRGFVYFVETLARSICEKLEQSGLPVGGNEKKAKLANVVRKMMTNSQD
TELSFTITGDNTKWNENQNPRMFLAMITYMTRNQPEWFRNVLSIAPIMFSNK
MARLGKGYMFESKSMKLRTQIPAEMLASIDLKYFNDSTRKKIEKIRSLLIEGT
ASLSPGMMMGMFNMLSTVLGVSILNLGQKRYTKTTYWWDGLQSSDDFALI
VNAPNHEGIQAGVDRFYRTCKLLGINMSKKKSYINRTGTFEFTSFFYRYGFV
ANFSMELPSFGVSGINESADMSIGVTVIKNNMINNDLGPATAQMALQLFIKDY
RYTYRCHRGDTQIQTRRSFEIKKLWEQTRSKAGLLVSDGGPNLYNIRNLHIP
EVCLKWELMDEDYQGRLCNPLNPFVSHKEIESMNNAVMMPAHGPAKNMEY
DAVATTHSWIPKRNRSILNTSQRGVLEDEQMYQRCCNLFEKFFPSSSYRRP
VGISSMVEAMVSRARIDARIDFESGRIKKEEFTEIMKICSTIEELRRQK 
>PB1-F2 
MGQEQDTPWILSTGHISTQKREDGQQTPKLEHRNSTRLMGHCQKTMNQVV
MPKQIVYWRRWLSLRNPILVFLKTRVLKRWRLFSKHE 
>PA 
MEDFVRQCFNPMIVELAEKTMKEYGEDLKIETNKFAAICTHLEVCFMYSDFH
FINEQGESIIVELGDPNALLKHRFEIIEGRDRTMAWTVVNSICNTTGAEKPKFL
PDLYDYKENRFIEIGVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKAD
YTLDEESRARIKTRLFTIRQEMASRGLWDSFRQSERGEETIEERFEITGTMR
KLADQSLPPNFSSLENFRAYVDGFEPNGYIEGKLSQMSKEVNARIEPFLKTT
PRPLRLPNGPPCSQRSKFLLMDALKLSIEDPSHEGEGIPLYDAIKCMRTFFG
WKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPKTKNMKKTSQLK
WALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACEL
TDSSWIELDEIGEDVAPIEHIASMRRNYFTSEVSHCRATEYIMKGVYINTALLN
ASCAAMDDFQLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSM
EFSLTDPRLEPHKWEKYCVLEIGDMLIRSAIGQVSRPMFLYVRTNGTSKIKM
KWGMEMRRCLLQSLQQIESMIEAESSVKEKDMTKEFFENKSETWPIGESPK
GVEESSIGKVCRTLLAKSVFNSLYASPQLEGFSAESRKLLLIVQALRDNLEPG
TFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALS 
>PA-N155 
MATKADYTLDEESRARIKTRLFTIRQEMASRGLWDSFRQSERGEETIEERFE
ITGTMRKLADQSLPPNFSSLENFRAYVDGFEPNGYIEGKLSQMSKEVNARIE
PFLKTTPRPLRLPNGPPCSQRSKFLLMDALKLSIEDPSHEGEGIPLYDAIKCM
RTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPKTKNMKKT
SQLKWALGENMAPEKVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNK
ACELTDSSWIELDEIGEDVAPIEHIASMRRNYFTSEVSHCRATEYIMKGVYIN
TALLNASCAAMDDFQLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVN
FVSMEFSLTDPRLEPHKWEKYCVLEIGDMLIRSAIGQVSRPMFLYVRTNGTS
KIKMKWGMEMRRCLLQSLQQIESMIEAESSVKEKDMTKEFFENKSETWPIG
ESPKGVEESSIGKVCRTLLAKSVFNSLYASPQLEGFSAESRKLLLIVQALRDN
LEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALS 
>PA-N182 
MASRGLWDSFRQSERGEETIEERFEITGTMRKLADQSLPPNFSSLENFRAY
VDGFEPNGYIEGKLSQMSKEVNARIEPFLKTTPRPLRLPNGPPCSQRSKFLL
MDALKLSIEDPSHEGEGIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLL
SWKQVLAELQDIENEEKIPKTKNMKKTSQLKWALGENMAPEKVDFDDCKDV
GDLKQYDSDEPELRSLASWIQNEFNKACELTDSSWIELDEIGEDVAPIEHIAS
MRRNYFTSEVSHCRATEYIMKGVYINTALLNASCAAMDDFQLIPMISKCRTK
EGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKYCVLE
IGDMLIRSAIGQVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMI
EAESSVKEKDMTKEFFENKSETWPIGESPKGVEESSIGKVCRTLLAKSVFNS
LYASPQLEGFSAESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVL
LNASWFNSFLTHALS 
>PA-X 
MEDFVRQCFNPMIVELAEKTMKEYGEDLKIETNKFAAICTHLEVCFMYSDFH
FINEQGESIIVELGDPNALLKHRFEIIEGRDRTMAWTVVNSICNTTGAEKPKFL
PDLYDYKENRFIEIGVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKAD
YTLDEESRARIKTRLFTIRQEMASRGLWDSFVSPREEKRQLKKGLKSQEQC
ASLPTKVSRRTSPALKILEPMWMDSNRTATLRASCLKCPKK 
>HA 
MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDS
HNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENG
ICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNGVTAACSHEGK
SSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLY
QNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEA
NGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHP
VTIGECPKYVRSAKLRMVTGLRNNPSIQSRGLFGAIAGFIEGGWTGMIDGWY
GYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFNKLE
KRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQL
KNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGV
KLESMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI 
>NP 
MASQGTKRSYEQMETDGERQNATEIRASVGKMIGGIGRFYIQMCTELKLSD
YEGRLIQNSLTIERMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYRRVNGK
WMRELILYDKEEIRRIWRQANNGDDATAGLTHMMIWHSNLNDATYQRTRAL
VRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGTMVMELVRMIKRGINDR
NFWRGENGRKTRIAYERMCNILKGKFQTAAQKAMMDQVRESRNPGNAEFE
DLTFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEREGYSLVGIDPFRLL
QNSQVYSLIRPNENPAHKSQLVWMACHSAAFEDLRVLSFIKGTKVLPRGKL
STRGVQIASNENMETMESSTLELRSRYWAIRTRSGGNTNQQRASAGQISIQ
PTFSVQRNLPFDRTTIMAAFNGNTEGRTSDMRTEIIRMMESARPEDVSFQG
RGVFELSDEKAASPIVPSFDMSNEGSYFFGDNAEEYDN 
>NA 
MNPNQKIITIGSICLVVGLISLILQIGNIISIWISHSIQTGSQNHTGICNQNIITYKN
STWVKDTTSVILTGNSSLCPIRGWAIYSKDNSIRIGSKGDVFVIREPFISCSHL
ECRTFFLTQGALLNDKHSSGTVKDRSPYRALMSCPVGEAPSPYNSRFESVA
WSASACHDGMGWLTIGISGPDNGAVAVLKYNGIITETIKSWRKKILRTQESE
CACVNGSCFTIMTDGPSDGLASYKIFKIEKGKVTKSIELNAPNSHYEECSCYP
DTGKVMCVCRDNWHGSNRPWVSFDQNLDYQIGYICSGVFGDNPRPEDGT
GSCGPVYVDGANGVKGFSYRYGNGVWIGRTKSHSSRHGFEMIWDPNGWT
ETDSKFSVRQDVVAMTDWSGYSGSFVQHPELTGLDCMRPCFWVELIRGRP
KEKTIWTSASSISFCGVNSDTVDWSWPDGAELPFSIDK 
>M1 
MSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEVLMEWLKTRPILSP
LTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLYRKLKR
EITFHGAKEISLSYSAGALASCMGLIYNRMGAVTTEVAFGLVCATCEQIADSQ
HRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQMAGSSEQAAEAMEVASQ
ARQMVQAMRTIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQRFK 
>M2 
MSLLTEVETPIRNEWGCRCNGSSDPLTIAANIIGILHLTLWILDRLFFKCIYRRF
KYGLKGGPSTEGVPKSMREEYRKEQQSAVDADDGHFVSIELE 
>M3 
MGVQMQRFK 
>M4 
MSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEAYQKRMGVQMQR
FK 
>M42 
MSLQGRTPILRPIRNEWGCRCNGSSDPLTIAANIIGILHLTLWILDRLFFKCIYR
RFKYGLKGGPSTEGVPKSMREEYRKEQQSAVDADDGHFVSIELE 
>NS1 
MDPNTVSSFQVDCFLWHVRKRVADQELGDAPFLDRLRRDQKSLRGRGSTL
GLDIKTATRAGKQIVERILKEESDEALKMTMASVPASRYLTDMTLEEMSRDW
SMLIPKQKVAGPLCIRMDQAIMDKNIILKANFSVIFDRLETLILLRAFTEEGAIV
GEISPLPSLPGHTAEDVKNAVGVLIGGLEWNDNTVRVSETLQRFAWRSSNE
NGRPPLTPKQKREMAGTIRSEV 
>NEP 
MDPNTVSSFQDILLRMSKMQLESSSEDLNGMITQFESLKLYRDSLGEAVMR
MGDLHSLQNRNEKWREQLGQKFEEIRWLIEEVRHKLKITENSFEQITFMQAL
HLLLEVEQEIRTFSFQLI 
>NS3 
MDPNTVSSFQVDCFLWHVRKRVADQELGDAPFLDRLRRDQKSLRGRGSTL
GLDIKTATRAGKQIVERILKEESDEALKMTMASVPASRYLTDMTLEEMSRDW
SMLIPKQKVAGPLCIRMDQAIMDHTAEDVKNAVGVLIGGLEWNDNTVRVSET
LQRFAWRSSNENGRPPLTPKQKREMAGTIRSEV 
>NEG8 
MLFAQNYSLLSSVCVSLLQSTILFLQTSDLIVPAISRFCFGVSGGLPFSLLLLQ
ANLCRVSETRTVLSFHSSPPMRTPTAFLTSSAVCPGREGNGEISPTIAPSSV
KALSNIRVSSRSKITLKFAFSMMFLSMIAWSILIQRGPATFCLGMSMDQSLDI
SSRVMSVR 
 
 
  
Figures 
Figure 1: Methods of Influenza Virion Purification 
 
Schematics outlining the stages in purifying influenza virions (a) with and (b) without 
haemadsorption (HAd). (c) A silver-stained SDS-PAGE gel showing proteins present 
in a sample of virions purified using HAd, with molecular weight markers shown in 
kDa. (d) Negative-stain transmission electron micrograph showing intact virions 
purified without HAd. Scale bar 200 nm; adapted from [12]. 
 
  
Figure 2: Stages in Influenza Virion Purification 
 
Photographs showing stages in the purification procedure outlined in Fig. 1a, 
purifying viruses grown in tissue culture using an OptiPrep density gradient. (a)-(c) 
Layering clarified virus growth medium onto a cushion, showing the overhanging 
angle used to minimise mixing. (d) Removal of the cushion after centrifugation, 
angling to avoid disrupting the pellet. (e) Addition of buffer to the pellets from six 
tubes for resuspension. Note the pot of Virkon solution for the immediate disposal of 
virus-contaminated waste. (f) Layering the pooled, resuspended pellets onto the top 
of a density gradient. (g) Density gradient after centrifugation. Virions are visible as a 
band just below the mid-point of the tube. (h) Harvesting virions by side puncture 
(fingers were kept well clear during the puncturing). Note the guide-marks made on 
the tube with pen (showing the initial levels of the meniscus and of the band of 
virions, the point just below the virions where the tube will be punctured, and an 
indication below the meniscus of how much fluid should be withdrawn), the torch 
clamped above and the use of a black background (in this case, a broken 
smartphone case). (i) Ejection of harvested virions into a fresh tube containing 
buffer. 
 
  
Figure 3: Sample Preparation for Mass Spectrometry 
 
A collection tube and 10 kDa MWCO filter, shown (a) separately and (b) assembled 
in a rack. (c) Illustration of how a filter can be used to concentrate and wash proteins. 
(d) Effect on a protein of reduction (with tris(2-carboxyethyl)phosphine hydrochloride, 
TCEP, affecting disulphide bonds) and alkylation (with iodoacetamide, IAA, to leave 
S-acetamide (AA) alkylations). (e) Illustration of how a filter can be used to collect 
peptides after digest. (f) Placing samples, loaded in a v-bottom 96-well plate, into a 
Dionex UltiMateTM 3000 autosampler for HPLC. (g) Injection of sample into a Q 
Exactive Hybrid Quadrupole-Orbitrap mass spectrometer.  
Figure 4: Summary of an influenza virion proteome. 
 
Viral and host proteins identified and quantified in a sample of MDCK-grown 
influenza A/Puerto Rico/8/1934 virus, using the methods described in this chapter. 
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